State Street Corporation filed a Schedule 13G with the SEC on November 10, 2026, disclosing beneficial ownership of 21,695,003 shares of Iovance Biotherapeutics Inc common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: State Street Corporation reported 21,695,003 shares of Iovance Biotherapeutics Inc common stock, representing 4.8% of the class.
  • Shared voting power: State Street disclosed shared power to vote or direct the vote on 20,523,410 shares.
  • Shared dispositive power: The filing reports shared power to dispose of or direct the disposition of 21,695,003 shares.
  • Sole voting and dispositive power: Both sole voting power and sole dispositive power are reported as 0 shares.
  • Filing date of event: The date of the event requiring the filing is listed as September 30, 2026.
  • Subsidiaries involved: The filing identifies five subsidiaries as the relevant entities, including SSGA Funds Management, Inc. and State Street Global Advisors Europe Limited, each classified as an investment adviser (IA).

State Street's Schedule 13G Ownership Disclosure for Iovance Biotherapeutics

State Street Corporation, organized in Massachusetts and headquartered at One Congress Street, Suite 1, Boston, MA 02114, filed a Schedule 13G disclosing its beneficial ownership position in Iovance Biotherapeutics Inc (NASDAQ:IOVA), whose principal offices are located at 999 Skyway Road Suite 150, San Carlos, California, 94070. The filing was signed by Alok Maheshwary, Senior Vice President, and dated November 9, 2026.

According to the filing, State Street's aggregate beneficial ownership stands at 21,695,003 shares of common stock (CUSIP 462260100), equal to 4.8% of the class. The filing reports no sole voting or dispositive power; instead, all reported power is shared. Shared voting power covers 20,523,410 shares, while shared dispositive power covers the full 21,695,003 shares.

The filing identifies five subsidiaries through which the securities were acquired: SSGA Funds Management, Inc.; State Street Global Advisors Europe Limited; State Street Global Advisors Limited; State Street Global Advisors Trust Company; and State Street Global Advisors, Ltd., each classified as an investment adviser. State Street certified, as required, that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The filing notes ownership of 5 percent or less of the class under Item 5.

What Was Disclosed

State Street Corporation disclosed a 4.8% beneficial ownership position in Iovance Biotherapeutics Inc common stock as of September 30, 2026, totaling 21,695,003 shares held with shared voting and dispositive power through five investment adviser subsidiaries.